Alerts Sign-up
The Christ Hospital Health Network in Cincinnati has commenced a new clinical study in collaboration with InterShunt Technologies, Inc., a company specializing in medical devices for heart failure treatment. The EASE HF2 Early Feasibility Study is assessing a device aimed at alleviating heart failure symptoms and enhancing the quality of life for patients.
Dr. Sitaramesh Emani and the Structural Heart Intervention Team at The Christ Hospital Health Network performed the first U.S. procedure using InterShunt’s technology. Dr. Emani remarked, “We’re excited to get this study started. The first procedure went smoothly, and the patient went home the next day feeling well. It’s an encouraging start, and we’re hopeful this treatment can help many more people.”
The focus of the study is on patients suffering from heart failure with reduced ejection fraction (HFrEF), where the heart's pumping ability is compromised, causing increased pressure within the heart. Current treatments are not effective for all patients, making this new approach potentially beneficial. The device functions by creating a small opening between the upper chambers of the heart to relieve built-up pressure without leaving any permanent implants.
Harlee Sorkin, CEO of InterShunt Technologies, stated, “This first enrollment is a big step for our team and for people living with heart failure. We are incredibly thankful to the patient, their family, and the team at The Christ Hospital for making this possible.” He emphasized that since no permanent implant is left behind, future treatment options remain available.
Heart failure remains a leading cause of hospitalization among adults over 65 years old and accounts for up to 5% of Medicare spending. Many patients do not find sufficient relief from existing medications; however, reducing pressure in the left atrium can improve symptoms and quality of life.
The Christ Hospital Health Network operates an acute care hospital in Mt. Auburn along with several other facilities throughout the region. It was recognized as the top hospital in Cincinnati by U.S. News & World Report and included in Newsweek’s World’s Best Hospitals list in 2025.
InterShunt Technologies is developing a catheter system designed to create an atrial shunt that reduces elevated left atrial pressure without using implants or energy-based methods. The EASE HF2 study plans to enroll 20 patients across up to six sites in the United States.
